Aaron Michels
Concepts (322)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 1 | 62 | 2024 | 3254 | 7.310 |
Why?
| Autoantigens | 15 | 2022 | 396 | 3.450 |
Why?
| Receptors, Antigen, T-Cell | 14 | 2023 | 615 | 3.440 |
Why?
| Insulin | 27 | 2021 | 2080 | 3.320 |
Why?
| Islets of Langerhans | 15 | 2023 | 728 | 2.740 |
Why?
| Autoantibodies | 20 | 2023 | 1347 | 2.380 |
Why?
| T-Lymphocytes | 12 | 2023 | 1735 | 2.110 |
Why?
| Antineoplastic Agents, Immunological | 4 | 2022 | 152 | 2.060 |
Why?
| Programmed Cell Death 1 Receptor | 4 | 2019 | 193 | 1.780 |
Why?
| Insulin-Secreting Cells | 9 | 2022 | 317 | 1.660 |
Why?
| Hypoglycemic Agents | 9 | 2020 | 1011 | 1.630 |
Why?
| CD4-Positive T-Lymphocytes | 14 | 2021 | 959 | 1.590 |
Why?
| Autoimmunity | 13 | 2022 | 812 | 1.450 |
Why?
| Antibodies, Monoclonal | 5 | 2020 | 1257 | 1.410 |
Why?
| Autoimmune Diseases | 5 | 2019 | 381 | 1.250 |
Why?
| Insulin Antibodies | 4 | 2017 | 102 | 1.190 |
Why?
| Peptides | 6 | 2023 | 848 | 1.190 |
Why?
| Histocompatibility Antigens Class II | 7 | 2018 | 350 | 1.090 |
Why?
| HLA-DQ Antigens | 7 | 2019 | 174 | 1.050 |
Why?
| Immunologic Factors | 3 | 2019 | 217 | 1.030 |
Why?
| HLA-DR Antigens | 3 | 2022 | 219 | 0.970 |
Why?
| Melanoma | 2 | 2022 | 620 | 0.930 |
Why?
| Antigen Presentation | 2 | 2018 | 188 | 0.910 |
Why?
| Protein Precursors | 3 | 2021 | 119 | 0.870 |
Why?
| B7-H1 Antigen | 3 | 2021 | 137 | 0.850 |
Why?
| Immunotherapy | 7 | 2021 | 473 | 0.830 |
Why?
| Cell Cycle Checkpoints | 2 | 2020 | 84 | 0.810 |
Why?
| Humans | 74 | 2024 | 114043 | 0.800 |
Why?
| Models, Immunological | 2 | 2015 | 90 | 0.800 |
Why?
| Peptide Fragments | 6 | 2016 | 665 | 0.800 |
Why?
| Methyldopa | 2 | 2019 | 7 | 0.770 |
Why?
| HLA Antigens | 3 | 2022 | 220 | 0.740 |
Why?
| HLA-DQ beta-Chains | 1 | 2020 | 57 | 0.690 |
Why?
| Disease Susceptibility | 1 | 2021 | 316 | 0.670 |
Why?
| Interferon-gamma | 2 | 2021 | 719 | 0.670 |
Why?
| Polyendocrinopathies, Autoimmune | 2 | 2010 | 18 | 0.670 |
Why?
| Health Fairs | 1 | 2019 | 9 | 0.660 |
Why?
| Antigens | 4 | 2018 | 317 | 0.650 |
Why?
| Stevens-Johnson Syndrome | 2 | 2019 | 34 | 0.650 |
Why?
| Preventive Medicine | 1 | 2018 | 38 | 0.600 |
Why?
| Alleles | 5 | 2022 | 789 | 0.580 |
Why?
| Proinsulin | 2 | 2017 | 48 | 0.570 |
Why?
| Child | 27 | 2022 | 18400 | 0.550 |
Why?
| Influenza, Human | 1 | 2022 | 543 | 0.550 |
Why?
| Antibody Formation | 1 | 2018 | 266 | 0.540 |
Why?
| Immunity, Cellular | 1 | 2018 | 247 | 0.530 |
Why?
| Dried Blood Spot Testing | 1 | 2016 | 71 | 0.520 |
Why?
| Graft Rejection | 1 | 2018 | 511 | 0.490 |
Why?
| Rituximab | 1 | 2016 | 148 | 0.490 |
Why?
| Adolescent | 24 | 2021 | 17800 | 0.490 |
Why?
| Major Histocompatibility Complex | 2 | 2013 | 217 | 0.490 |
Why?
| Hypoglycemia | 3 | 2016 | 386 | 0.480 |
Why?
| Protein Kinase Inhibitors | 1 | 2020 | 784 | 0.470 |
Why?
| Lymphocyte Activation | 4 | 2020 | 1036 | 0.470 |
Why?
| HLA-D Antigens | 1 | 2014 | 34 | 0.470 |
Why?
| Diet Therapy | 1 | 2014 | 36 | 0.460 |
Why?
| Mass Screening | 3 | 2019 | 979 | 0.460 |
Why?
| Biomarkers | 3 | 2021 | 3397 | 0.460 |
Why?
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 4 | 2019 | 58 | 0.460 |
Why?
| Drug Hypersensitivity | 1 | 2015 | 83 | 0.450 |
Why?
| Addison Disease | 1 | 2014 | 40 | 0.450 |
Why?
| Adrenal Glands | 1 | 2014 | 66 | 0.450 |
Why?
| Antibodies | 1 | 2015 | 365 | 0.440 |
Why?
| Disease Progression | 6 | 2021 | 2371 | 0.430 |
Why?
| Blood Glucose | 4 | 2024 | 1827 | 0.430 |
Why?
| Hormone Replacement Therapy | 1 | 2014 | 76 | 0.430 |
Why?
| Mice, Inbred NOD | 7 | 2018 | 552 | 0.420 |
Why?
| Prediabetic State | 1 | 2015 | 219 | 0.400 |
Why?
| Genetic Predisposition to Disease | 7 | 2021 | 2090 | 0.390 |
Why?
| Diabetic Ketoacidosis | 3 | 2020 | 161 | 0.380 |
Why?
| Female | 35 | 2022 | 59325 | 0.380 |
Why?
| Male | 32 | 2022 | 55396 | 0.370 |
Why?
| Young Adult | 16 | 2021 | 10444 | 0.370 |
Why?
| Animals | 21 | 2023 | 31565 | 0.370 |
Why?
| Organophosphorus Compounds | 1 | 2011 | 72 | 0.360 |
Why?
| Glycine | 1 | 2011 | 152 | 0.360 |
Why?
| Epitopes | 4 | 2021 | 434 | 0.360 |
Why?
| Immunosuppressive Agents | 1 | 2014 | 641 | 0.350 |
Why?
| Carcinoma, Papillary, Follicular | 1 | 2010 | 8 | 0.350 |
Why?
| Struma Ovarii | 1 | 2010 | 7 | 0.350 |
Why?
| Adult | 27 | 2023 | 30375 | 0.340 |
Why?
| Macromolecular Substances | 1 | 2010 | 200 | 0.340 |
Why?
| Endocrine System Diseases | 1 | 2010 | 30 | 0.340 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 309 | 0.330 |
Why?
| Child, Preschool | 13 | 2021 | 9114 | 0.320 |
Why?
| C-Peptide | 5 | 2016 | 138 | 0.320 |
Why?
| Neoplasms | 2 | 2020 | 2086 | 0.310 |
Why?
| Inflammation | 2 | 2017 | 2464 | 0.300 |
Why?
| Transcription Factor 7-Like 2 Protein | 2 | 2018 | 24 | 0.300 |
Why?
| Haplotypes | 3 | 2020 | 448 | 0.300 |
Why?
| Diabetes Mellitus, Type 2 | 2 | 2020 | 2087 | 0.300 |
Why?
| Middle Aged | 20 | 2022 | 26605 | 0.300 |
Why?
| Carbamazepine | 2 | 2019 | 18 | 0.290 |
Why?
| CD8-Positive T-Lymphocytes | 3 | 2021 | 686 | 0.290 |
Why?
| Pediatrics | 1 | 2015 | 982 | 0.290 |
Why?
| Infant | 9 | 2022 | 7943 | 0.290 |
Why?
| Glutamate Decarboxylase | 4 | 2017 | 160 | 0.280 |
Why?
| Blood Glucose Self-Monitoring | 2 | 2024 | 505 | 0.260 |
Why?
| Antilymphocyte Serum | 2 | 2016 | 60 | 0.250 |
Why?
| Granulocyte Colony-Stimulating Factor | 2 | 2016 | 70 | 0.250 |
Why?
| Ovarian Neoplasms | 1 | 2010 | 386 | 0.250 |
Why?
| History, 21st Century | 2 | 2018 | 160 | 0.250 |
Why?
| History, 20th Century | 2 | 2018 | 265 | 0.240 |
Why?
| Pluripotent Stem Cells | 2 | 2022 | 64 | 0.230 |
Why?
| Mice | 11 | 2023 | 14841 | 0.230 |
Why?
| Protein Binding | 3 | 2021 | 1888 | 0.220 |
Why?
| Hybridomas | 3 | 2020 | 230 | 0.220 |
Why?
| Lipodystrophy, Congenital Generalized | 1 | 2023 | 1 | 0.210 |
Why?
| Lipodystrophy | 1 | 2023 | 16 | 0.210 |
Why?
| CD3 Complex | 2 | 2020 | 92 | 0.210 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 787 | 0.190 |
Why?
| T-Lymphocytes, Regulatory | 2 | 2022 | 337 | 0.190 |
Why?
| Histocompatibility Antigens | 1 | 2021 | 98 | 0.180 |
Why?
| Polyethylene Glycols | 2 | 2016 | 561 | 0.180 |
Why?
| Insulin, Regular, Human | 1 | 2020 | 33 | 0.180 |
Why?
| Clinical Trials as Topic | 2 | 2018 | 926 | 0.180 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2018 | 1880 | 0.180 |
Why?
| Molecular Sequence Data | 3 | 2015 | 2783 | 0.180 |
Why?
| Glucagon-Like Peptides | 1 | 2020 | 22 | 0.180 |
Why?
| Rhizotomy | 1 | 2000 | 3 | 0.180 |
Why?
| Virus Diseases | 2 | 2015 | 195 | 0.180 |
Why?
| Case-Control Studies | 3 | 2022 | 3003 | 0.180 |
Why?
| Brachial Plexus | 1 | 2000 | 28 | 0.170 |
Why?
| Histocompatibility Antigens Class I | 1 | 2021 | 170 | 0.170 |
Why?
| Retroviridae | 1 | 2020 | 89 | 0.170 |
Why?
| Stem Cells | 2 | 2021 | 541 | 0.170 |
Why?
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2019 | 7 | 0.170 |
Why?
| Immunoassay | 1 | 2020 | 95 | 0.170 |
Why?
| Muscle Spasticity | 1 | 2000 | 53 | 0.170 |
Why?
| Diagnostic Techniques, Endocrine | 1 | 2019 | 14 | 0.170 |
Why?
| Arm | 1 | 2000 | 104 | 0.170 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 437 | 0.160 |
Why?
| Blood Specimen Collection | 1 | 2019 | 31 | 0.160 |
Why?
| Prognosis | 2 | 2018 | 3315 | 0.160 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 660 | 0.160 |
Why?
| Genotype | 2 | 2015 | 1757 | 0.160 |
Why?
| HLA-DRB1 Chains | 1 | 2019 | 97 | 0.160 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 154 | 0.160 |
Why?
| Models, Molecular | 2 | 2015 | 1368 | 0.160 |
Why?
| Treatment Outcome | 5 | 2019 | 9049 | 0.150 |
Why?
| Cell Line, Transformed | 1 | 2018 | 133 | 0.150 |
Why?
| Tissue Donors | 2 | 2021 | 314 | 0.150 |
Why?
| Transglutaminases | 2 | 2016 | 142 | 0.150 |
Why?
| High-Throughput Screening Assays | 1 | 2019 | 123 | 0.150 |
Why?
| Community Health Services | 1 | 2019 | 212 | 0.140 |
Why?
| Antibodies, Viral | 1 | 2021 | 520 | 0.140 |
Why?
| Genetic Heterogeneity | 1 | 2017 | 47 | 0.140 |
Why?
| Treatment Failure | 1 | 2018 | 330 | 0.140 |
Why?
| Mutation | 3 | 2015 | 3338 | 0.140 |
Why?
| Amino Acid Sequence | 3 | 2017 | 1981 | 0.140 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2016 | 27 | 0.140 |
Why?
| Genetic Variation | 1 | 2021 | 868 | 0.140 |
Why?
| Radioimmunoassay | 1 | 2016 | 161 | 0.140 |
Why?
| Mice, Transgenic | 2 | 2019 | 1947 | 0.130 |
Why?
| Luminescence | 1 | 2016 | 33 | 0.130 |
Why?
| Administration, Oral | 1 | 2018 | 725 | 0.130 |
Why?
| Donor Selection | 1 | 2016 | 65 | 0.130 |
Why?
| Dideoxynucleosides | 1 | 2015 | 20 | 0.130 |
Why?
| Luminescent Measurements | 1 | 2016 | 74 | 0.120 |
Why?
| Immunologic Memory | 1 | 2017 | 313 | 0.120 |
Why?
| Antigen-Presenting Cells | 1 | 2015 | 150 | 0.120 |
Why?
| Monocytes | 2 | 2016 | 503 | 0.120 |
Why?
| Abatacept | 1 | 2014 | 40 | 0.120 |
Why?
| Multifactorial Inheritance | 1 | 2015 | 122 | 0.120 |
Why?
| Sequence Homology, Amino Acid | 1 | 2015 | 353 | 0.120 |
Why?
| Vitamin B Complex | 1 | 2014 | 38 | 0.110 |
Why?
| Niacinamide | 1 | 2014 | 63 | 0.110 |
Why?
| Pharmacogenetics | 1 | 2015 | 149 | 0.110 |
Why?
| B-Lymphocytes | 1 | 2019 | 762 | 0.110 |
Why?
| Early Medical Intervention | 1 | 2014 | 52 | 0.110 |
Why?
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2014 | 97 | 0.110 |
Why?
| Aged | 5 | 2021 | 18969 | 0.110 |
Why?
| Chromogranin A | 1 | 2013 | 39 | 0.110 |
Why?
| Colorado | 2 | 2021 | 4090 | 0.110 |
Why?
| Immunoconjugates | 1 | 2014 | 87 | 0.110 |
Why?
| CD4 Antigens | 1 | 2013 | 123 | 0.110 |
Why?
| Diabetes Mellitus | 1 | 2021 | 898 | 0.110 |
Why?
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2013 | 43 | 0.110 |
Why?
| Incidence | 1 | 2019 | 2314 | 0.110 |
Why?
| Secondary Prevention | 1 | 2014 | 221 | 0.110 |
Why?
| Interleukin-10 | 1 | 2015 | 293 | 0.110 |
Why?
| Primary Prevention | 1 | 2014 | 172 | 0.100 |
Why?
| Myeloid Cells | 1 | 2014 | 126 | 0.100 |
Why?
| alpha 1-Antitrypsin | 1 | 2014 | 102 | 0.100 |
Why?
| Celiac Disease | 1 | 2016 | 264 | 0.100 |
Why?
| Multiprotein Complexes | 1 | 2014 | 140 | 0.100 |
Why?
| Kidney Transplantation | 1 | 2018 | 538 | 0.100 |
Why?
| Amino Acid Motifs | 1 | 2013 | 197 | 0.100 |
Why?
| Pancreas, Artificial | 1 | 2013 | 68 | 0.100 |
Why?
| Polymorphism, Genetic | 1 | 2015 | 610 | 0.100 |
Why?
| Sulfhydryl Compounds | 1 | 2014 | 176 | 0.100 |
Why?
| Alum Compounds | 1 | 2011 | 22 | 0.090 |
Why?
| Skin Neoplasms | 1 | 2018 | 754 | 0.090 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 296 | 0.090 |
Why?
| Cytokines | 2 | 2017 | 1824 | 0.090 |
Why?
| Small Molecule Libraries | 1 | 2011 | 79 | 0.090 |
Why?
| Dendritic Cells | 1 | 2014 | 435 | 0.090 |
Why?
| Structure-Activity Relationship | 1 | 2011 | 499 | 0.090 |
Why?
| Thyroglobulin | 1 | 2010 | 17 | 0.090 |
Why?
| Dietary Proteins | 1 | 2011 | 121 | 0.090 |
Why?
| Whole Body Imaging | 1 | 2010 | 19 | 0.090 |
Why?
| Radionuclide Imaging | 1 | 2010 | 115 | 0.090 |
Why?
| Diagnosis, Differential | 1 | 2014 | 1331 | 0.080 |
Why?
| Thyroidectomy | 1 | 2010 | 62 | 0.080 |
Why?
| Iatrogenic Disease | 1 | 2010 | 47 | 0.080 |
Why?
| Iodine Radioisotopes | 1 | 2010 | 126 | 0.080 |
Why?
| Hysterectomy | 1 | 2010 | 105 | 0.080 |
Why?
| Immune Tolerance | 1 | 2011 | 321 | 0.080 |
Why?
| Self Tolerance | 1 | 2009 | 28 | 0.080 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2014 | 1204 | 0.080 |
Why?
| Organ Specificity | 1 | 2010 | 266 | 0.080 |
Why?
| Mice, Inbred BALB C | 1 | 2011 | 1144 | 0.080 |
Why?
| Adrenal Insufficiency | 1 | 2009 | 26 | 0.080 |
Why?
| Sensitivity and Specificity | 3 | 2019 | 1690 | 0.080 |
Why?
| Interferon-alpha | 1 | 2010 | 185 | 0.080 |
Why?
| Interleukin-2 | 1 | 2010 | 413 | 0.080 |
Why?
| Syndrome | 1 | 2009 | 330 | 0.080 |
Why?
| Mice, Inbred C57BL | 2 | 2017 | 4680 | 0.070 |
Why?
| Vaccines | 1 | 2011 | 375 | 0.070 |
Why?
| Gene Expression Regulation | 1 | 2015 | 2321 | 0.070 |
Why?
| Area Under Curve | 2 | 2016 | 273 | 0.060 |
Why?
| Histocompatibility Testing | 2 | 2017 | 115 | 0.060 |
Why?
| Leukocytes, Mononuclear | 2 | 2019 | 489 | 0.060 |
Why?
| Risk Assessment | 1 | 2014 | 2958 | 0.060 |
Why?
| Prospective Studies | 3 | 2023 | 6195 | 0.060 |
Why?
| Cell Differentiation | 2 | 2022 | 1695 | 0.050 |
Why?
| Models, Biological | 1 | 2010 | 1611 | 0.050 |
Why?
| Perilipin-1 | 1 | 2023 | 16 | 0.050 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2022 | 11 | 0.050 |
Why?
| HLA-A2 Antigen | 1 | 2021 | 35 | 0.050 |
Why?
| Transcription Factors | 1 | 2009 | 1525 | 0.050 |
Why?
| Psychology, Child | 1 | 1981 | 37 | 0.050 |
Why?
| Seroepidemiologic Studies | 1 | 2021 | 137 | 0.040 |
Why?
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 92 | 0.040 |
Why?
| Neurologic Examination | 1 | 2000 | 113 | 0.040 |
Why?
| HLA-B15 Antigen | 1 | 2019 | 13 | 0.040 |
Why?
| NFATC Transcription Factors | 1 | 2020 | 78 | 0.040 |
Why?
| Hand Strength | 1 | 2000 | 97 | 0.040 |
Why?
| Psychotic Disorders | 1 | 1981 | 114 | 0.040 |
Why?
| Genes, Reporter | 1 | 2020 | 256 | 0.040 |
Why?
| Flow Cytometry | 2 | 2014 | 1075 | 0.040 |
Why?
| Hand | 1 | 2000 | 135 | 0.040 |
Why?
| Adipose Tissue | 1 | 2023 | 545 | 0.040 |
Why?
| Epitopes, T-Lymphocyte | 1 | 2020 | 170 | 0.040 |
Why?
| Genetic Vectors | 1 | 2020 | 287 | 0.040 |
Why?
| Phosphoproteins | 1 | 2021 | 293 | 0.040 |
Why?
| Adoptive Transfer | 1 | 2019 | 194 | 0.040 |
Why?
| Antibody Specificity | 1 | 2018 | 175 | 0.040 |
Why?
| Cohort Studies | 2 | 2018 | 4883 | 0.040 |
Why?
| Gene Editing | 1 | 2018 | 57 | 0.040 |
Why?
| Cell- and Tissue-Based Therapy | 1 | 2018 | 56 | 0.040 |
Why?
| Immunization | 1 | 2020 | 397 | 0.040 |
Why?
| Molecular Dynamics Simulation | 1 | 2019 | 200 | 0.040 |
Why?
| Lymphocytes | 1 | 2019 | 327 | 0.040 |
Why?
| Stem Cell Transplantation | 1 | 2018 | 148 | 0.040 |
Why?
| Gene Frequency | 1 | 2018 | 476 | 0.040 |
Why?
| HEK293 Cells | 1 | 2019 | 590 | 0.030 |
Why?
| Receptors, CXCR3 | 1 | 2016 | 15 | 0.030 |
Why?
| CD56 Antigen | 1 | 2016 | 34 | 0.030 |
Why?
| Receptors, IgG | 1 | 2016 | 67 | 0.030 |
Why?
| Graft Survival | 1 | 2018 | 443 | 0.030 |
Why?
| Zinc Transporter 8 | 1 | 2016 | 86 | 0.030 |
Why?
| Forkhead Transcription Factors | 1 | 2016 | 170 | 0.030 |
Why?
| Cation Transport Proteins | 1 | 2016 | 123 | 0.030 |
Why?
| Skin | 1 | 2019 | 653 | 0.030 |
Why?
| Prevalence | 1 | 2021 | 2247 | 0.030 |
Why?
| Overweight | 1 | 2018 | 473 | 0.030 |
Why?
| Risk Factors | 2 | 2018 | 8614 | 0.030 |
Why?
| T-Lymphocyte Subsets | 1 | 2016 | 383 | 0.030 |
Why?
| Single-Blind Method | 1 | 2014 | 259 | 0.030 |
Why?
| Chromatography, Ion Exchange | 1 | 2014 | 48 | 0.030 |
Why?
| Gastrins | 1 | 2013 | 8 | 0.030 |
Why?
| Chromatography, Gel | 1 | 2014 | 122 | 0.030 |
Why?
| Colesevelam Hydrochloride | 1 | 2013 | 7 | 0.030 |
Why?
| Drug Combinations | 1 | 2014 | 286 | 0.030 |
Why?
| Dimerization | 1 | 2014 | 176 | 0.030 |
Why?
| Allylamine | 1 | 2013 | 7 | 0.030 |
Why?
| Sodium-Glucose Transporter 1 | 1 | 2013 | 10 | 0.030 |
Why?
| Bromocriptine | 1 | 2013 | 26 | 0.030 |
Why?
| Sodium-Glucose Transporter 2 | 1 | 2013 | 17 | 0.030 |
Why?
| Cells, Cultured | 1 | 2021 | 3861 | 0.030 |
Why?
| Killer Cells, Natural | 1 | 2016 | 380 | 0.030 |
Why?
| Surface Plasmon Resonance | 1 | 2014 | 81 | 0.030 |
Why?
| Risk | 1 | 2016 | 810 | 0.030 |
Why?
| Sulfonylurea Compounds | 1 | 2013 | 44 | 0.030 |
Why?
| Recombinant Proteins | 1 | 2016 | 1228 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2016 | 1078 | 0.030 |
Why?
| Islet Amyloid Polypeptide | 1 | 2013 | 47 | 0.030 |
Why?
| Primary Cell Culture | 1 | 2013 | 148 | 0.030 |
Why?
| Toll-Like Receptors | 1 | 2014 | 167 | 0.030 |
Why?
| Statistics, Nonparametric | 1 | 2014 | 384 | 0.030 |
Why?
| Glucagon-Like Peptide 1 | 1 | 2013 | 100 | 0.030 |
Why?
| Thiazolidinediones | 1 | 2013 | 142 | 0.030 |
Why?
| Leptin | 1 | 2013 | 210 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2019 | 2764 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2019 | 2537 | 0.020 |
Why?
| Interleukin-1beta | 1 | 2014 | 368 | 0.020 |
Why?
| Baculoviridae | 1 | 2011 | 44 | 0.020 |
Why?
| Diabetic Angiopathies | 1 | 2013 | 246 | 0.020 |
Why?
| Down-Regulation | 1 | 2014 | 594 | 0.020 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 315 | 0.020 |
Why?
| Oxidation-Reduction | 1 | 2014 | 917 | 0.020 |
Why?
| Thymus Gland | 1 | 2011 | 296 | 0.020 |
Why?
| Metformin | 1 | 2013 | 274 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2019 | 3498 | 0.020 |
Why?
| Phenotype | 1 | 2017 | 2784 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2016 | 2384 | 0.020 |
Why?
| Postoperative Complications | 1 | 2000 | 2122 | 0.020 |
Why?
| Gene Expression | 1 | 2013 | 1417 | 0.020 |
Why?
| Signal Transduction | 1 | 2020 | 4501 | 0.020 |
Why?
| Obesity | 1 | 2018 | 2505 | 0.020 |
Why?
| Time Factors | 1 | 2016 | 6077 | 0.020 |
Why?
| Registries | 1 | 2013 | 1764 | 0.020 |
Why?
| Cross-Sectional Studies | 1 | 2013 | 4402 | 0.010 |
Why?
| Cardiovascular Diseases | 1 | 2013 | 1726 | 0.010 |
Why?
| Aged, 80 and over | 1 | 2013 | 6306 | 0.010 |
Why?
| Language Development Disorders | 1 | 1981 | 38 | 0.010 |
Why?
| Mother-Child Relations | 1 | 1981 | 109 | 0.010 |
Why?
| Child Behavior Disorders | 1 | 1981 | 131 | 0.010 |
Why?
| United States | 1 | 2013 | 12137 | 0.010 |
Why?
| Family | 1 | 1981 | 589 | 0.010 |
Why?
| Communication | 1 | 1981 | 734 | 0.010 |
Why?
|
|
Michels's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|